Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients
UP-CAPTAIn
1 other identifier
interventional
107
1 country
2
Brief Summary
The goal of this prospective randomized study is to improve antibiotic use among hospitalized patients with suspected pneumonia. An alert was built into the electronic health record to guide use of diagnostic testing based on probability of bacterial pneumonia. Patients with test results suggesting viral infection will be randomized to either: (1) receive a structured communication from the antimicrobial stewardship team to de-escalate antibiotics or (2) usual care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Nov 2023
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 11, 2023
CompletedFirst Posted
Study publicly available on registry
August 4, 2023
CompletedStudy Start
First participant enrolled
November 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 10, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2025
CompletedApril 14, 2026
April 1, 2026
1.2 years
July 11, 2023
April 10, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Hospital antibiotic days of therapy
The aggregate sum of days for which any amount of a specific antimicrobial agent was administered during the hospital encounter, from arrival in the emergency department or on the hospital ward until discharge.
Up to 90 days after randomization
Secondary Outcomes (8)
Hospital length of stay
Up to 90 days after randomization
In-hospital mortality
Up to 90 days after randomization
Readmissions within 30-days of randomization
Within 30 days after randomization
C. difficile infections in the 30-days post-randomization
Within 30 days after randomization
Acute kidney injury
Within 14 days of randomization
- +3 more secondary outcomes
Study Arms (2)
Electronic alert plus structured communication of test results
EXPERIMENTALAn electronic health record alert will guide diagnostic testing for pneumonia. For patients with low or moderate probability of bacterial pneumonia, test results will be communicated to the primary team with guidance to consider discontinuing or de-escalating antibiotics.
Electronic alert without structured communication of test results
ACTIVE COMPARATORAn electronic health record alert will guide diagnostic testing for pneumonia. The primary care team will access and interpret test results and decide upon composition and duration of antimicrobial without external guidance.
Interventions
An alert will appear in the electronic health record that provides options for diagnostic testing based on low, medium, or high probability of bacterial pneumonia.
A clinical research team member will send an electronic message to the primary care team on behalf of the antimicrobial stewardship program with structured guidance to stop or de-escalate antibiotics and document these recommendations in the patient's chart.
Eligibility Criteria
You may qualify if:
- Adult patients admitted to the University of Maryland Medical Center or University of Maryland Medical Center-Midtown Campus who are prescribed antibiotics for suspected community-acquired respiratory infection.
- Protocol-based diagnostic testing supports possible viral infection, either by positive molecular test or low procalcitonin value.
You may not qualify if:
- Hospitalization for \>72 hours prior to protocol-based diagnostic testing.
- Previous molecular testing for viral infection during the same hospital encounter.
- Severely immunosuppressed, defined as having hematologic malignancy, solid organ tumor on chemotherapy, or solid organ transplant on immunosuppression
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Jonathan Baghdadilead
- Centers for Disease Control and Preventioncollaborator
Study Sites (2)
University of Maryland Medical Center - Midtown Campus
Baltimore, Maryland, 21201, United States
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
Related Publications (1)
Baghdadi JD, Harris AD, Pineles L, Al-Shanqeeti S, Palacio D, Charles DW, Heil E, Claeys KC, Bork JT, Sommerkamp S, Wilkerson RG, Godwin G, Sutherland ME, Johnson JK, Morgan DJ. Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients: A Pragmatic, Randomized Trial. Clin Infect Dis. 2026 Mar 13:ciag126. doi: 10.1093/cid/ciag126. Online ahead of print.
PMID: 41823187RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Daniel J. Morgan, MD, MS
University of Maryland, Baltimore
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
July 11, 2023
First Posted
August 4, 2023
Study Start
November 1, 2023
Primary Completion
January 10, 2025
Study Completion
May 31, 2025
Last Updated
April 14, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share